<DOC>
	<DOCNO>NCT01013961</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer kill substance . Giving rituximab together alemtuzumab may kill cancer cell . PURPOSE : This randomized phase II trial study two different dos rituximab compare well work give together alemtuzumab treat old patient progressive chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Rituximab Alemtuzumab Treating Older Patients With Progressive Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare rate complete overall response elderly patient progressive chronic lymphocytic leukemia ( CLL ) treat one two dos rituximab combine alemtuzumab determine use modified-dose rituximab significantly affect outcome . Secondary - To monitor assess toxicity regimen . - To determine overall progression-free survival , time clinical response , time next treatment , duration response patient treat regimen - To assess correlation risk stratification prognostic marker ( i.e. , CD38 , ZAP-70 , fluorescent situ hybridization ( FISH ) , IgVH mutation ) clinical outcome . - To assess response regimen use 1996 National Cancer Institute Working Group ( NCI-WG 96 ) criterion expand definition response patient complete remission , include immunohistochemical examination bone marrow sensitive flow cytometry ( 4-6 color ) blood minimal residual disease compute tomography ( CT ) scan residual adenopathy . - To determine mechanism action rituximab alemtuzumab determine mechanism resistance subpopulation CLL cell drug . OUTLINE : This multicenter study . Patients stratify accord FISH risk ( low [ 13q14- ] v intermediate [ 12+ , abnormality , abnormality ] vs high [ 17p13-,11q22- ] ) . Patients randomize 1 2 treatment arm . - Arm A : Patients receive alemtuzumab subcutaneously ( SC ) day 1-3 , 6 , 8 , 10 , 13 , 15 , 17 , 20 , 22 , 24 , 27 , 29 , 31 standard-dose rituximab intravenously ( IV ) day 8 , 15 , 22 , 29 cycle 1 ( 33-day cycle ) . In cycle 2 subsequent cycle ( 28-day cycle ) , patient receive alemtuzumab SC day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 standard-dose rituximab IV day 3 , 10 , 17 , 24 . Treatment repeat every 28 day 3 cycle . - Arm B : Patients receive alemtuzumab arm A . Patients also receive low-dose rituximab IV day 6 , 8 , 10 , 13 , 15 , 17 , 20 , 22 , 24 , 27 , 29 , 31 cycle 1 day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 cycle 2 3 . Treatment repeat every 28 day 3 cycle . Blood bone marrow sample collect periodically cytogenetic biomarker analysis . Alemtuzumab dose Cycle 1 Week 1 Arms A B require 'dose ramp ' ( 3 mg day 1 , 10 mg day2 , 30 mg day 3 cycle 1 ) . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis chronic lymphocytic leukemia ( CLL ) meeting follow criterion : Minimum threshold peripheral lymphocyte count 5 x 10^9/L ( CLL variant ) OR palpable adenopathy &gt; 1 cm palpable splenomegaly 9small lymphocytic lymphoma [ SLL ] variant ) Immunophenotypic demonstration population Blymphocytes ( define CD19+ ) monoclonal ( lightchain exclusion ) AND ≥ 3 follow characteristic : CD5+ CD23+ Dim surface light chain expression Dim surface CD20 expression FISH analysis negative immunoglobulin heavy chain/cyclin D1 gene ( IGH/CCND1 ) and/or immunostaining negative cyclin D1 expression ( exclude mantle cell lymphoma ) Progressive , symptomatic CLL , define least one following : Weight loss &gt; 10 % within past 6 month attributable progressive CLL ( grade 2 high ) Extreme fatigue attributable progressive CLL ( grade 3 high ) Fevers &gt; 100.5° F 2 week without evidence infection ( grade 1 high ) Night sweat without evidence infection ( drench ) Evidence progressive bone marrow failure hemoglobin &lt; 11 g/dL platelet count &lt; 100 x 10^9/L Rapidly progressive lymphadenopathy large node ≤ 5 cm dimension Largest lymph node involve neck , axilla , groin need measure follow response Prior treatment CLL Massive splenomegaly &gt; 6 cm leave costal margin , rest , clinical examination Lymphadenopathy &gt; 5 cm diameter New York Heart Association class III IV heart disease Recent myocardial infarction ( within past month ) Uncontrolled infection Infection human immunodeficiency virus ( HIV/AIDS ) Serological evidence active hepatitis B infection ( HBsAg HBeAg positive ) Positive hepatitis C serology Evidence active autoimmune hemolytic anemia , immune thrombocytopenia , pure red blood cell aplasia Other active primary malignancy require treatment limit survival ≤ 2 year , except situ carcinoma cervix breast nonmetastatic basal cell squamous cell carcinoma skin Major surgery within 4 week prior preregistration Concomitant use continuous systemic corticosteroid Prior corticosteroid allow time preregistration study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>CLL</keyword>
	<keyword>elderly</keyword>
	<keyword>low dose rituximab</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>